A kind of multi-target anticancer drug and its preparation method and application
An anti-cancer drug, multi-target technology, applied in the field of medicine, can solve problems such as disorder and apoptosis disorder, and achieve the effect of strong binding affinity and obvious non-peptide characteristics
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0049] Embodiment 1 (multi-target anticancer drug G 1 )
[0050] The synthesis method of compound A (the structural formula of compound A is shown in formula II) refers to the preparation method in paragraphs [0046] to [0083] of Chinese patent 201610036840.2.
[0051] (S)-2-((5R,8S,10aR)-5-(tert-butoxycarboxamido)-6-carbonylthiazepine[1,5]pyrrolidine[2,1-d]- Preparation of 8-carboxamido)-3-phenylpropionic acid methyl ester (compound B):
[0052]
[0053] At -10°C, L-phenylalanine methyl ester hydrochloride (62mg, 0.29mmol), EDCI (572mg, 2.9mmol), HOBt (392mg, 2.9mmol) were added to compound A (99mg, 0.29mmol) Dry the dichloromethane (10 mL) solution, and then add DIEA to adjust the pH of the reaction solution to alkaline. The mixture was stirred overnight at room temperature, then diluted with dichloromethane, and washed successively with dilute hydrochloric acid solution, saturated sodium carbonate solution, and saturated brine. The organic phase was dried over anhydro...
Embodiment 2
[0066] Embodiment 2 (multi-target anticancer drug G 2 )
[0067] The synthesis method of compound A (the structural formula of compound A is shown in formula VI) refers to the preparation method in paragraphs [0046] to [0083] of Chinese patent 201610036840.2.
[0068] (R)-2-((5R,8S,10aR)-5-(tert-butoxycarboxamido)-6-carbonylthiazepine[1,5]pyrrolidine[2,1-d]- 8-Carboxamido)-3-phenylpropanoic acid methyl ester (Compound B)
[0069]
[0070] At 0°C, D-phenylalanine methyl ester hydrochloride (188mg, 0.87mmol), DCC (1196mg, 5.8mmol), HOOBt (946mg, 5.8mmol) were added to the dry solution of compound A (99mg, 0.29mmol) dichloromethane solution (15 mL), and then added triethylamine to adjust the pH of the reaction solution to alkaline. The mixture was stirred overnight at room temperature, then diluted with dichloromethane, and washed successively with saturated ammonium chloride solution, saturated sodium bicarbonate solution, and saturated brine. The organic phase was dried ...
Embodiment 3
[0082] Embodiment 3 (compound G 3 )
[0083] The synthesis method of compound A refers to the preparation method in paragraphs [0046] to [0083] of Chinese patent 201610036840.2.
[0084] (S)-2-((5R,8S,10aR)-5-(tert-butoxycarboxamido)-6-carbonylthiazepine[1,5]pyrrolidine[2,1-d]- Preparation of 8-carboxamido)-3-phenylpropionic acid methyl ester (compound B):
[0085]
[0086] At 15°C, L-phenylalanine methyl ester hydrochloride (313mg, 1.45mmol), BOP (128mg, 0.29mmol), HOSu (8mg, 0.07mmol) were added to the dry solution of compound A (99mg, 0.29mmol) Chloroform solution (5 mL), and then add pyridine to adjust the pH of the reaction solution to alkaline. The mixture was stirred overnight at room temperature, then diluted with chloroform, and washed successively with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated brine. The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Th...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


